DaVita Inc. (NYSE:DVA) Shares Acquired by Ethic Inc.

Ethic Inc. lifted its stake in shares of DaVita Inc. (NYSE:DVA) by 116.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,345 shares of the company’s stock after purchasing an additional 2,340 shares during the quarter. Ethic Inc.’s holdings in DaVita were worth $650,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. United Capital Financial Advisors LLC raised its position in shares of DaVita by 2.6% during the 4th quarter. United Capital Financial Advisors LLC now owns 2,416 shares of the company’s stock worth $361,000 after purchasing an additional 62 shares during the period. Freedom Investment Management Inc. grew its holdings in DaVita by 3.6% in the 4th quarter. Freedom Investment Management Inc. now owns 1,790 shares of the company’s stock worth $268,000 after buying an additional 62 shares in the last quarter. Exchange Traded Concepts LLC grew its holdings in DaVita by 8.3% in the 4th quarter. Exchange Traded Concepts LLC now owns 891 shares of the company’s stock worth $133,000 after buying an additional 68 shares in the last quarter. Impact Partnership Wealth LLC grew its holdings in DaVita by 3.7% in the 4th quarter. Impact Partnership Wealth LLC now owns 1,941 shares of the company’s stock worth $290,000 after buying an additional 70 shares in the last quarter. Finally, Contravisory Investment Management Inc. grew its holdings in DaVita by 1.2% in the 4th quarter. Contravisory Investment Management Inc. now owns 6,082 shares of the company’s stock worth $910,000 after buying an additional 73 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Barclays increased their price objective on DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 18th. Cowen reissued a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. StockNews.com raised DaVita from a “hold” rating to a “buy” rating in a report on Friday, April 25th. Finally, Sanford C. Bernstein set a $184.00 price objective on DaVita in a report on Friday, February 21st. One analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, DaVita currently has an average rating of “Hold” and a consensus price target of $166.33.

DaVita Stock Performance

Shares of NYSE DVA opened at $140.10 on Thursday. The stock has a fifty day moving average price of $145.87 and a two-hundred day moving average price of $153.58. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The firm has a market cap of $10.77 billion, a P/E ratio of 13.04, a PEG ratio of 1.07 and a beta of 1.14. DaVita Inc. has a 1 year low of $131.44 and a 1 year high of $179.60.

DaVita (NYSE:DVA) last released its quarterly earnings data on Monday, May 12th. The company reported $2.00 earnings per share for the quarter, topping the consensus estimate of $1.75 by $0.25. The business had revenue of $3.22 billion during the quarter, compared to analyst estimates of $3.22 billion. DaVita had a return on equity of 115.48% and a net margin of 7.31%. The company’s revenue was up 5.0% compared to the same quarter last year. During the same period last year, the company posted $2.26 EPS. Research analysts forecast that DaVita Inc. will post 10.76 EPS for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.